Oncopeptides AB: INTERIM REPORT Q1 2019

May 21, 2019   |   May 2019 Bond Updates
STOCKHOLM, May 21, 2019 /PRNewswire/ -- "The initiation of the filing process for melflufen in the US is a major milestone for Oncopeptides." Financial overview January 1 – March 31, 2019 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 122.2 M (loss: 62.0) Loss per...

View more at: https://www.prnewswire.com:443/news-releases/oncopeptides-ab-interim-report-q1-2019-300853766.html
 
Related News
Home| About us | Contact us http://www.bondupdatesdailynews.com/